search
Back to results

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention (BHB-CRC)

Primary Purpose

Colorectal Cancer

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
R-1,3-Butanediol
Sponsored by
Abramson Cancer Center at Penn Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age of 18 years or older
  • Scheduled for a colonoscopy or flexible sigmoidoscopy as part of the patient's standard care
  • Can provide informed consent

Exclusion Criteria:

  • Subject is pregnant, a prisoner, or is under 18 years of age
  • Patient is not able to undergo colonoscopy or flexible sigmoidoscopy
  • Prior total proctocolectomy
  • History of inflammatory bowel disease
  • History of diabetes mellitus and are currently on medical diabetes therapy
  • History of chronic kidney disease with an eGFR < 60 mL/min/1.73m2
  • Cancer diagnosis where the subject is receiving active therapy
  • Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment

Sites / Locations

  • Abramson Cancer Center of the University of Pennsylvania

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BHB supplementation

Arm Description

Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.

Outcomes

Primary Outcome Measures

Determine whether oral BHB supplementation is safe and tolerable
Assessment of patient tolerance of BHB supplements through weekly monitoring of side effects and/or intolerances and patient compliance. We will monitor the percentage of individuals who continue through Visit 2, and the percentage continuing through Visit 3, as well as the compliance with taking the BHB supplement.

Secondary Outcome Measures

Determine whether oral BHB supplementations increases serum BHB levels
Assessment of fasting serum BHB levels before, during, and after BHB supplementation to determine if BHB supplementation appreciably increases serum BHB levels.
Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
Comparison of both transcription and protein changes in the colonic mucosa from mucosal biopsies before and after BHB supplementation to determine if BHB supplementation is having measurable effects on the colonic mucosa.

Full Information

First Posted
April 14, 2022
Last Updated
April 25, 2023
Sponsor
Abramson Cancer Center at Penn Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05338307
Brief Title
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
Acronym
BHB-CRC
Official Title
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 19, 2022 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abramson Cancer Center at Penn Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.
Detailed Description
The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy in order to determine whether BHB supplementation is safe and tolerable. Additionally, this study will determine whether BHB supplementations increases serum BHB levels, and leads to transcription and protein expression changes in the colonic mucosa. BHB supplementation will be performed through oral administration of HVMN Ketone-IQ, a commercially available BHB supplement, with an active ingredient of R-1,3-Butanediol, which gets converted to BHB.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BHB supplementation
Arm Type
Experimental
Arm Description
Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
R-1,3-Butanediol
Intervention Description
Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
Primary Outcome Measure Information:
Title
Determine whether oral BHB supplementation is safe and tolerable
Description
Assessment of patient tolerance of BHB supplements through weekly monitoring of side effects and/or intolerances and patient compliance. We will monitor the percentage of individuals who continue through Visit 2, and the percentage continuing through Visit 3, as well as the compliance with taking the BHB supplement.
Time Frame
Through study completion, which will be approximately 2 years
Secondary Outcome Measure Information:
Title
Determine whether oral BHB supplementations increases serum BHB levels
Description
Assessment of fasting serum BHB levels before, during, and after BHB supplementation to determine if BHB supplementation appreciably increases serum BHB levels.
Time Frame
Through study completion, which will be approximately 2 years
Title
Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
Description
Comparison of both transcription and protein changes in the colonic mucosa from mucosal biopsies before and after BHB supplementation to determine if BHB supplementation is having measurable effects on the colonic mucosa.
Time Frame
Through study completion, which will be approximately 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age of 18 years or older Scheduled for a colonoscopy or flexible sigmoidoscopy as part of the patient's standard care Can provide informed consent Exclusion Criteria: Subject is pregnant, a prisoner, or is under 18 years of age Patient is not able to undergo colonoscopy or flexible sigmoidoscopy Prior total proctocolectomy History of inflammatory bowel disease History of diabetes mellitus and are currently on medical diabetes therapy History of chronic kidney disease with an eGFR < 60 mL/min/1.73m2 Cancer diagnosis where the subject is receiving active therapy Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bryson W Katona, MD, PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Abramson Cancer Center of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention

We'll reach out to this number within 24 hrs